CrossRef Cited By Search Results

This article [doi:10.1038/sj.bjc.6602692] has been cited in the following papers, taken from those publishers and societies that are participating in CrossRef's Cited-by Linking service. The number of citations from this service is usually lower than citation numbers from databases that include more journals.

BACK TO ARTICLE

  1. EISSN: 15737217 ISSN: 01676806

    Breast Cancer Research and Treatment

    Cost-effectiveness of exemestane versus tamoxifen as adjuvant therapy for early-stage breast cancer after 2–3 years treatment with tamoxifen in Sweden

    Jonas Lundkvist, Nils Wilking, Stig Holmberg, Linus Jönsson

    102 (3), 2007, p.289

    doi:10.1007/s10549-006-9333-6

  2. EISSN: 15251497 ISSN: 08848734

    Journal of General Internal Medicine

    The Expanding Use of Third-Generation Aromatase Inhibitors: What the General Internist Needs to Know

    Susan Hong, Aarati Didwania, Olufunmilayo Olopade, Pamela Ganschow

    24 (s2), 2009, p.383

    doi:10.1007/s11606-009-1037-2

  3. EISSN: 10991557 ISSN: 10538569

    Pharmacoepidemiology and Drug Safety

    Current awareness: Pharmacoepidemiology and drug safety

    15 (2), 2006, p.i

    doi:10.1002/pds.1175

  4. EISSN: 17434262 ISSN: 17434254

    Nature Clinical Practice Oncology

    Should women with early hormone-responsive breast cancer be switched from tamoxifen to anastrozole?

    Alexander HG Paterson

    3 (2), 2006, p.80

    doi:10.1038/ncponc0427

  5. EISSN: 17421241 ISSN: 13685031

    International Journal of Clinical Practice

    The what, why and how of aromatase inhibitors: hormonal agents for treatment and prevention of breast cancer

    C. J. Fabian

    61 (12), 2007, p.2051

    doi:10.1111/j.1742-1241.2007.01587.x

  6. EISSN: 17448336 ISSN: 14787210

    Expert Review of Anticancer Therapy

    Effects of adjuvant aromatase inhibitor therapy on lipid profiles

    Alain Monnier

    6 (11), 2006, p.1653

    doi:10.1586/14737140.6.11.1653

  7. EISSN: 15737217 ISSN: 01676806

    Breast Cancer Research and Treatment

    Multicenter phase II trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer: Saitama Breast Cancer Clinical Study Group (SBCCSG-03)

    Hiroyuki Takei et al.

    107 (1), 2007, p.87

    doi:10.1007/s10549-007-9529-4

  8. EISSN: 15326535 ISSN: 00099236

    Clinical Pharmacology & Therapeutics

    Estrogen Receptor Genotypes, Menopausal Status, and the Lipid Effects of Tamoxifen

    NI Ntukidem et al.

    83 (5), 2008, p.702

    doi:10.1038/sj.clpt.6100343

  9. EISSN: 10970142 ISSN: 0008543X

    Cancer

    Genetic polymorphisms of CYP2D6*10 and CYP2C19*2,*3 are not associated with prognosis, endometrial thickness, or bone mineral density in Japanese breast cancer patients treated with adjuvant tamoxifen

    Masatsugu Okishiro et al.

    115 (5), 2009, p.952

    doi:10.1002/cncr.24111

BACK TO ARTICLE